GSK (LON:GSK) Full Year 2024 Results

Key Financial Results

• Revenue: UK£31.4b (up 3.5% from FY 2023).
• Net income: UK£2.58b (down 48% from FY 2023).
• Profit margin: 8.2% (down from 16% in FY 2023).
• EPS: UK£0.63 (down from UK£1.22 in FY 2023).

GSK Products In Clinical Trials

• Phase I: 27.
• Phase II: 35.
• Phase III: 23.

GSK Post-Clinical Trial Products

• Pre-registration: 1.
• Approved (during full year): 4.
• Launched (during full year): 2.

All figures shown in the chart above are for the trailing 12 month (TTM) period

GSK EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 25%.

The primary driver behind last 12 months revenue was the United States (US) segment contributing a total revenue of UK£16.4b (52% of total revenue). The largest operating expense was General & Administrative costs, amounting to UK£10.9b (54% of total expenses). Explore how GSK's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Pharmaceuticals industry in the United Kingdom.

Performance of the British Pharmaceuticals industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

Before you take the next step you should know about the 4 warning signs for GSK that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.